X.com Signal Deep Dive
Social intelligence signals from X.com with engagement and sentiment analysis
Keyword Group Distribution
Transportation remains the #1 barrier for Alzheimer's trial participants in Tampa Bay. We need sponsors to invest in patient support programs. @ClinicalTrials @AlzAssociation
Thread: Why biomarker-driven enrollment is the future of AD trials. AI-powered screening can reduce screen failure by 40%. Here's what we've learned from 3 trials... (1/12)
Excited to announce that our AD-CLARITY trial has reached 75% enrollment target ahead of schedule! Thank you to our dedicated site teams and participants. #ClinicalTrials
Decentralized and hybrid trial designs are no longer optional — they're the standard. We're committed to supporting innovation in clinical research. Full statement: [link]
My mom just completed her 6-month visit in an Alzheimer's trial. The remote monitoring made it so much easier for us as caregivers. More trials should adopt this approach.
Real talk: clinical trial coordinators are burning out. Between manual data entry, protocol amendments, and regulatory overhead, we're losing good people. AI can't come fast enough.
Clinical trial AI market expected to reach $4.2B by 2028. Key players to watch: companies combining real-time intelligence with autonomous site operations. #HealthTech #AI
Only 5% of AD trial participants are Hispanic, despite being at 1.5x higher risk. We need AI-driven outreach that meets communities where they are, not just academic medical centers.